Topics

Articles

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

BioNTech, BMS to Co-Design and Co-Commercialize New Antibody Candidate for Various Types of Tumors

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one. 

The Tariff Effect: Greater Supply Chain Prepares for Repercussions 

This serialization system represents a business imperative that yields significant competitive advantages.

Serialization 2.0: Why It’s Time to Upgrade, and What’s at Stake

The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

Mercalis and PharmaCord Officially Merge, Form Valeris

Videos

In the final part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes best practices for balancing long-term pipeline sustainability with short-term financial returns.

A Balancing Act

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, explains how GLP-1 therapies’ success can influence future investment strategies in high unmet need areas.

The GLP-1 Effect

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

Noom to Sell Microdoses of Wegovy

The partnership is centered around cutting cold chain costs and emissions with smart packaging and carbon-neutral same-day delivery.

Invensify, Go2 Delivery Collaborate on Temperature-Controlled Courier Service

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, outlines strategies that companies can adopt to help mitigate these increasing costs.

How to Manage Rising Drug Development Costs

In the first part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, shares the key factors that he believes are propelling a continued rise in projected R&D ROI.  

Business and Finance